What they were paid
Monte Rosa Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $49,167 | $0 | $107,686 | $0 | $156,853 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Monte Rosa Therapeutics, Inc. DEF 14A filed April 29, 2026, accession 0001193125-26-191439, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Monte Rosa Therapeutics pays directors a $40,000 cash retainer.
Committees
FY2025 · as the proxy prints themNominating/Governance (Chair)
The rest of the Monte Rosa Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Ali Behbahani, M.D | Independent Director | $155,186 |
| Andrew Schiff, M.D | Independent Director | $186,853 |
| Anthony Manning, Ph.D | Independent Director | $159,769 |
| Chandra P. Leo, M.D | Independent Director | $0 |
| Christine Siu | Independent Director | $162,686 |
| Eric Hughes, M.D., Ph.D | Independent Director | $150,603 |
| Kimberly L. Blackwell, M.D | Independent Director | $162,686 |
| Markus Warmuth, M.D | Director | $0 |
The full Monte Rosa Therapeutics compensation record
free company briefThis page is one director within Monte Rosa Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat